diamsar chelate

structure given in first source; chelating agent, coordinate with metal being chelated

Also Known As:

1,8-diamino-3,6,10,13,16,19-hexaazabicyclo(6,6,6)eicosane; NH2-Sar-cage; diamine-sarcophagine; diamsar

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Baumhover, Nicholas J: 1 article (07/2011)
2.	Giangrande, Paloma H: 1 article (07/2011)
3.	Huang, Ling: 1 article (07/2011)
4.	Kloepping, Kyle C: 1 article (07/2011)
5.	Rockey, William M: 1 article (07/2011)
6.	Schultz, Michael K: 1 article (07/2011)
7.	Achilefu, Samuel: 1 article (04/2009)
8.	Anderson, Carolyn J: 1 article (04/2009)
9.	Lewis, Jason S: 1 article (04/2009)
10.	Wadas, Thaddeus J: 1 article (04/2009)

1.	Prostatic Neoplasms (Prostate Cancer) 07/01/2011 - "Three commercially available bifunctional macrocyclic chelators (1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid mono N-hydroxysuccinimide [DOTA-NHS]; S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid [p-SCN-Bn-NOTA]; and p-SCN-Bn-3,6,9,15-tetraazabicyclo [9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid [p-SCN-Bn-PCTA]), as well as the polyamino-macrocyclic diAmSar (3,6,10,13,16,19-hexaazabicyclo[6.6.6] icosane-1,8-diamine) were conjugated to A10-3.2, a RNA aptamer which has been shown to bind specifically to a prostate cancer-specific cell-surface antigen (PSMA). "
2.	Neoplasms (Cancer) 04/01/2009 - "For diamsar-c(RGDfD), a linker may be needed between the Cu-chelator moiety and the RGD peptide to achieve optimal in vivo tumor concentration and clearance from nontarget organs."

1.	Chelating Agents
2.	Nucleotide Aptamers
3.	Diamines
4.	Surface Antigens (Surface Antigen)
5.	Acids
6.	DOTA-NHS
7.	triazacyclononane
8.	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)
9.	arginyl-glycyl-aspartic acid
10.	N-hydroxysuccinimide